The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine
Abstract
Rationale Recently, a new putative animal model of anxiety, "light-enhanced startle" was introduced. By placing a rat in a brightly lit environment, which is a naturally aversive stimulus to rats, the amplitude of the startle response to a startle-eliciting noise burst is increased. Objectives The present study aimed to determine the predictive validity of the light-enhanced startle as a putative model for anxiety. Methods The effects of the GABA(A)-benzodiazepine receptor agonist chlordiazepoxide (CDP), the 5-HT1A receptor agonist flesinoxan and the specific 5-HT reuptake inhibitor fluvoxamine on light-enhanced startle were studied. Results Both CDP and flesinoxan decreased startle potentiation, whereas fluvoxamine was devoid of any effects on potentiation. Effects on baseline startle amplitude were only seen after CDP administration. Conclusions The present experiment provides evidence for the predictive validity of the light-enhanced startle as an animal model for anxiety. Due to the use of an unconditioned anxiogenic stimulus, the light-enhanced startle offers several benefits over animal models that depend on conditioning. Drug effects can be ascribed more directly to effects on anxiety, as opposed to memory retrieval and, as shown in this study, non-specific drug effects can easily be detected without the interference of contextual fear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Light-enhanced startle was reduced selectively by both benzodiazepine (ie, chlordiazepoxide) and non-benzodiazepine (ie, flesinoxan, buspirone, and propranolol) anxiolytics (de Jongh et al, 2002; Walker and Davis, 1997a, 2002a).”
From Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety (2010) · cites this paper as de Jongh et al, 2002
Citations
Cites
Koch, M. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00098-7 · Cited by 1,287
Fear-potentiated startle: A neural and pharmacological analysis
Davis, M., Falls, W. A., Campeau, S., & Kim, M. (1993) · Behavioural Brain Research · doi:10.1016/0166-4328(93)90102-v · Cited by 748
Walker, D. L., & Davis, M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-23-09375.1997 · Cited by 627
DAVIS, M., WALKER, D. L., & LEE, Y. (1997) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1997.tb48289.x · Cited by 281
5HT drugs in animal models of anxiety
Handley, S. L., & McBlane, J. W. (1993) · Psychopharmacology · doi:10.1007/bf02247358 · Cited by 253
Anxiogenic effects of high illumination levels assessed with the acoustic startle response in rats
Walker, D. L., & Davis, M. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00441-6 · Cited by 211
Clinical utility of the selective serotonin reuptake inhibitors in the spectrum of anxiety
Kent, J. M., Coplan, J. D., & Gorman, J. M. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00210-8 · Cited by 196
Darkness facilitates the acoustic startle reflex in humans
Grillon, C., Pellowski, M., Merikangas, K. R., & Davis, M. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00466-0 · Cited by 193
Rodgers, R. J., Perrault, G., Sanger, D. J., & Griebel, G. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00402-9 · Cited by 190
Predictive validity of the potentiated startle response as a behavioral model for anxiolytic drugs
Hijzen, T. H., Houtzager, S. W. J., Joordens, R. J. E., Olivier, B., & Slangen, J. L. (1995) · Psychopharmacology · doi:10.1007/bf02245833 · Cited by 90
Self-citation
Cited by
Phasic vs Sustained Fear in Rats and Humans: Role of the Extended Amygdala in Fear vs Anxiety
Davis, M., Walker, D. L., Miles, L., & Grillon, C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.109 · Cited by 1,513
“Lightenhanced startle was reduced selectively by both benzodiazepine (ie, chlordiazepoxide) and non-benzodiazepine (ie, flesinoxan, buspirone, and propranolol) anxiolytics (de Jongh et al, 2002; Walker and Davis, 1997a, 2002a).”
BackgroundRole of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety
Walker, D. L., Toufexis, D. J., & Davis, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01282-2 · Cited by 838
Neural systems involved in fear and anxiety measured with fear-potentiated startle.
Davis, M. (2006) · American Psychologist · doi:10.1037/0003-066x.61.8.741 · Cited by 592
Models and mechanisms of anxiety: evidence from startle studies
Grillon, C. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1019-1 · Cited by 456
Walker, D. L., Miles, L. A., & Davis, M. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.06.022 · Cited by 331
Metadata
- Authors
- de Jongh, R., Groenink, L., van der Gugten, J., & Olivier, B.
- Affiliations
- Utrecht University (NL)
- Venue
- Psychopharmacology
- Published
- 2001-09-22
- Volume
- 159
- Issue
- 2
- Pages
- 176-180
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2075112843
- Cited by
- 70
- References
- 15
- Citations by year
- 2023: 1 · 2022: 1 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 5
- FWCI
- 1.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Keywords
- animal models of anxiety, predictive validity, chlordiazepoxide, flesinoxan, fluvoxamine, GABA-benzodiazepine receptor complex, 5-HT1A receptor, 5-HT reuptake inhibitors, startle potentiation, contextual fear
- MeSH terms
- Animals, Anxiety, Chlordiazepoxide, Darkness, Disease Models, Animal, Light, Male, Piperazines, Reflex, Startle, Anti-Anxiety Agents, Fluvoxamine, Rats, Wistar, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine. https://app.cochat.ai/papers/10.1007/s002130100914
- The paper
- de Jongh, R., Groenink, L., van der Gugten, J., & Olivier, B. (2002). The light-enhanced startle paradigm as a putative animal model for anxiety: effects of chlordiazepoxide, flesinoxan and fluvoxamine. Psychopharmacology. https://doi.org/10.1007/s002130100914
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.